Version 2.5.2.0 CRISP Logo CRISP Homepage Help for CRISP Email Us

Abstract

Grant Number: 5R21AT003482-02
Project Title: Probiotic Lactobacillus-Mediated Suppression of TNF in Pediatric Crohn's Disease
PI Information:NameEmailTitle
VERSALOVIC, JAMES jamesv@bcm.edu

Abstract: DESCRIPTION (provided by applicant): Probiotics, or beneficial bacteria, are promising agents for the prevention and treatment of pediatric inflammatory bowel disease (IBD). Several Lactobacillus species are considered to be probiotic organisms with attractive immunoregulatory features and are being consumed as nutritional supplements or alternative medicines. The proposed studies aim to comprehend basic mechanisms of immunoregulation by probiotics so that natural or engineered probiotics can be rationally devised for future medical therapies. The overall hypothesis is that probiotic Lactobacillus reuteri strains release oligosaccharides that suppress human tumor necrosis factor-alpha (TNF-a) by transcriptional regulation. Lactobacillus reuteri represents a model probiotic organism because this species has an impeccable safety record and has demonstrated beneficial effects in human individuals and mouse IBD models. L. reuteri is an established probiotic species that represents one of a select few indigenous Lactobacillus species of the human intestine. The specific aims of the proposal are as follows. 1) Investigate the relative abilities of Lactobacillus reuteri-derived oligosaccharides to inhibit human TNF-a by transcriptional regulation in primary human macrophages. Probiotic-derived oligosaccharide-enriched HPLC fractions from probiotic strains will be tested for TNF-inhibitory activity using primary cells derived from children with active Crohn's disease. 2) Explore suppression of AP-1-mediated transcriptional regulation of human TNF-a and modulation of MAP kinase signaling pathways in macrophages by probiotic oligosaccharides. Human macrophage models (two cell lines) that depend on either Toll-like receptor 2 (TLR2) or Toll-like receptor 4 (TLR4) signaling will be used to examine how probiotic oligosaccharides modulate MAP kinase signaling pathways. The identification of human signaling pathways regulated by probiotics will facilitate specification of targets for new anti-inflammatory compounds and may move probiotics from "alternative" to "mainstream" medicine.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
Crohn's disease, Lactobacillus, human, suppression
alternative medicine, bacteria, cell, cell line, children, immunoregulation, inflammatory bowel disease, intestine, macrophage, medicine, mitogen activated protein kinase, model, oligosaccharide, organism, prevention, therapy, toll like receptor, tumor necrosis factor alpha
clinical research

Institution: BAYLOR COLLEGE OF MEDICINE
1 BAYLOR PLAZA
HOUSTON, TX 770303498
Fiscal Year: 2008
Department: PATHOLOGY
Project Start: 01-JUL-2007
Project End: 30-JUN-2009
ICD: NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE
IRG: ZAT1


CRISP Homepage Help for CRISP Email Us